Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
QsL4Aw6QCsVxpZcp
Listen
